Universe Pharmaceuticals INC SEC filings UPC
Universe Pharmaceuticals INC has 119 filings in SEC EDGAR's recent list, going back to Apr 24, 2020. Its latest annual report, Form 20-F, was filed on Jan 29, 2026 for the period ended Sep 30, 2025. The most recent current report (Form 6-K) was filed on Oct 6, 2026. The company's fiscal year ends on September 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Oct 9, 2026 | — |
| 6-K | Current report (foreign issuer) | Oct 6, 2026 | Oct 6, 2026 |
| F-3 | Shelf registration (foreign issuer) | Sep 29, 2026 | — |
| 6-K/A | Amendment no. 1 to form 6-k | Sep 3, 2026 | Sep 3, 2026 |
| 6-K | Current report (foreign issuer) | Sep 1, 2026 | Sep 1, 2026 |
| 6-K | Current report (foreign issuer) | Jul 31, 2026 | Jul 31, 2026 |
| 6-K | Current report (foreign issuer) | Jul 29, 2026 | Mar 31, 2026 |
| 6-K | Current report (foreign issuer) | Jun 26, 2026 | Jun 26, 2026 |
| 6-K | Current report (foreign issuer) | May 14, 2026 | May 14, 2026 |
| 6-K | Current report (foreign issuer) | Apr 16, 2026 | Apr 16, 2026 |
| 6-K | Current report (foreign issuer) | Feb 11, 2026 | Feb 11, 2026 |
| 20-F | Annual report (foreign issuer) | Jan 29, 2026 | Sep 30, 2025 |
| 6-K | Current report (foreign issuer) | Sep 3, 2025 | Sep 3, 2025 |
| 6-K | Current report (foreign issuer) | Aug 26, 2025 | Aug 26, 2025 |
| 6-K | Current report (foreign issuer) | Jul 29, 2025 | Jul 29, 2025 |
| 6-K | Current report (foreign issuer) | Jul 3, 2025 | Jul 3, 2025 |
| 20-F | Annual report (foreign issuer) | Apr 29, 2025 | Sep 30, 2024 |
| 6-K | Current report (foreign issuer) | Mar 20, 2025 | Mar 20, 2025 |
| 6-K | Current report (foreign issuer) | Mar 11, 2025 | Mar 11, 2025 |
| 6-K | Current report (foreign issuer) | Mar 3, 2025 | Mar 3, 2025 |
| 6-K | Current report (foreign issuer) | Feb 25, 2025 | Feb 25, 2025 |
| 6-K | Current report (foreign issuer) | Feb 20, 2025 | Feb 20, 2025 |
| 6-K | Current report (foreign issuer) | Feb 18, 2025 | Feb 18, 2025 |
| 6-K | Current report (foreign issuer) | Feb 11, 2025 | Feb 11, 2025 |
| 6-K | Current report (foreign issuer) | Feb 3, 2025 | Feb 3, 2025 |
| 6-K | Current report (foreign issuer) | Jan 30, 2025 | Jan 30, 2025 |
| NT 20-F | Notification of late filing | Jan 27, 2025 | Sep 30, 2024 |
| 6-K | Current report (foreign issuer) | Dec 12, 2024 | Dec 12, 2024 |
| 424B5 | Prospectus supplement | Dec 9, 2024 | — |
| 6-K | Current report (foreign issuer) | Nov 13, 2024 | Nov 13, 2024 |
| 6-K | Current report (foreign issuer) | Nov 1, 2024 | Nov 1, 2024 |
| 6-K | Current report (foreign issuer) | Oct 10, 2024 | Oct 10, 2024 |
| 6-K | Current report (foreign issuer) | Sep 27, 2024 | Sep 27, 2024 |
| 6-K | Current report (foreign issuer) | Sep 20, 2024 | Mar 31, 2024 |
| 6-K | Current report (foreign issuer) | Sep 3, 2024 | Sep 3, 2024 |
| 6-K | Current report (foreign issuer) | Jul 18, 2024 | Jul 18, 2024 |
| 424B4 | Prospectus | Jun 25, 2024 | — |
| EFFECT | Filing | Jun 7, 2024 | — |
| CORRESP | Letter to the SEC | Jun 5, 2024 | — |
| CORRESP | Letter to the SEC | May 14, 2024 | — |
| F-1/A | Amendment no. 1 to form f-1 | May 14, 2024 | — |
| UPLOAD | Letter from the SEC | May 8, 2024 | — |
| F-1 | Registration statement (foreign issuer) | Apr 24, 2024 | — |
| 6-K | Current report (foreign issuer) | Feb 7, 2024 | Feb 7, 2024 |
| 20-F | Annual report (foreign issuer) | Jan 30, 2024 | Sep 30, 2023 |
| 6-K | Current report (foreign issuer) | Aug 31, 2023 | Mar 31, 2023 |
| 6-K | Current report (foreign issuer) | Aug 16, 2023 | Aug 16, 2023 |
| 6-K | Current report (foreign issuer) | Aug 4, 2023 | Aug 4, 2023 |
| 6-K | Current report (foreign issuer) | Jul 27, 2023 | Jul 27, 2023 |
| 6-K | Current report (foreign issuer) | Jul 5, 2023 | Jul 5, 2023 |
| 6-K | Current report (foreign issuer) | May 24, 2023 | May 24, 2023 |
| 6-K | Current report (foreign issuer) | May 5, 2023 | May 5, 2023 |
| 20-F | Annual report (foreign issuer) | Feb 10, 2023 | Sep 30, 2022 |
| NT 20-F | Notification of late filing | Jan 30, 2023 | Sep 30, 2022 |
| EFFECT | Filing | Nov 15, 2022 | — |
| 6-K | Current report (foreign issuer) | Nov 14, 2022 | Nov 14, 2022 |
| F-3 | Shelf registration (foreign issuer) | Oct 27, 2022 | — |
| 6-K | Current report (foreign issuer) | Sep 28, 2022 | Sep 28, 2022 |
| 6-K | Current report (foreign issuer) | Aug 29, 2022 | Aug 29, 2022 |
| 6-K | Current report (foreign issuer) | Aug 16, 2022 | Mar 31, 2022 |
| 6-K | Current report (foreign issuer) | Jul 19, 2022 | Jul 19, 2022 |
| 6-K | Current report (foreign issuer) | Jan 31, 2022 | Jan 31, 2022 |
| 20-F | Annual report (foreign issuer) | Jan 31, 2022 | Sep 30, 2021 |
| 6-K | Current report (foreign issuer) | Dec 15, 2021 | Dec 15, 2021 |
| 6-K | Current report (foreign issuer) | Dec 10, 2021 | Dec 10, 2021 |
| 6-K | Current report (foreign issuer) | Dec 9, 2021 | Dec 9, 2021 |
| 6-K | Current report (foreign issuer) | Aug 2, 2021 | Aug 2, 2021 |
| 6-K | Current report (foreign issuer) | Mar 31, 2021 | Mar 31, 2021 |
| 6-K | Current report (foreign issuer) | Mar 25, 2021 | Mar 25, 2021 |
| 424B4 | Prospectus | Mar 24, 2021 | — |
| EFFECT | Filing | Mar 22, 2021 | — |
| CERT | Filing | Mar 22, 2021 | — |
| CORRESP | Letter to the SEC | Mar 17, 2021 | — |
| CORRESP | Letter to the SEC | Mar 17, 2021 | — |
| 8-A12B | Form 8-a12b | Mar 17, 2021 | — |
| CORRESP | Letter to the SEC | Mar 10, 2021 | — |
| F-1/A | Amendment no. 4 to form f-1 | Mar 10, 2021 | — |
| UPLOAD | Letter from the SEC | Mar 2, 2021 | — |
| FWP | Free writing prospectus | Mar 1, 2021 | — |
| FWP | Free writing prospectus | Mar 1, 2021 | — |
| F-1/A | Amendment no. 3 to form f-1 | Feb 24, 2021 | — |
| FWP | Free writing prospectus | Dec 10, 2020 | — |
| CORRESP | Letter to the SEC | Dec 2, 2020 | — |
| F-1/A | Amendment no.2 to form f-1 | Dec 2, 2020 | — |
| UPLOAD | Letter from the SEC | Nov 19, 2020 | — |
| CORRESP | Letter to the SEC | Nov 17, 2020 | — |
| F-1/A | Amendment no. 1 to form f-1 | Nov 17, 2020 | — |
| FWP | Free writing prospectus | Sep 23, 2020 | — |
| UPLOAD | Letter from the SEC | Sep 1, 2020 | — |
| CORRESP | Letter to the SEC | Aug 17, 2020 | — |
| F-1 | Registration statement (foreign issuer) | Aug 17, 2020 | — |
| UPLOAD | Letter from the SEC | Jun 24, 2020 | — |
| DRSLTR | Filing | Jun 12, 2020 | — |
| DRS/A | Filing | Jun 12, 2020 | — |
| UPLOAD | Letter from the SEC | May 20, 2020 | — |
| DRS | Filing | Apr 24, 2020 | — |
Showing 96 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- UPC (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- China
- Headquarters
- Ji'An, Jiangxi, China
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1809616
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.